Aug 01, 2014, by NelsonHall Analyst
Genpact’s Q2 2014 results show similar mid-single digit (5%) top line growth to Q1 (4.9%), in line with prior guidance for the year of 4%-6% (this has now been adjusted to 5-7% to include a revenue contribution from its Q2 acquisition of Pharmalink). But it is substantially below the 12.1% growth seen in 2013.
EBIT margin was 13.0%, down both sequentially (-7 bps) and y/y (-157 bps[...]
Sep 02, 2013, by NelsonHall Analyst
NGA's performance is in keeping with the HRO market which has been buoyant in recent months. The division's revenue will have been boosted by the Convergys acquisition as well as wining new contracts (e.g. Aer Lingus) and successful renewals (e.g. Fifth Third Bank).
The restructuring of NPS division last year, to focus more on services, combined with a number of contracts starting in 20[...]